Israel - ebraică - Ministry of Health

novartis israel ltd - pazopanib as hydrochloride - טבליות מצופות פילם - pazopanib as hydrochloride 200 mg - pazopanib - pazopanib - renal cell carcinoma (rcc)votrient is indicated in adults for the first line treatment of advanced renal cell carcinoma (rcc) and for patients who have received prior cytokine therapy for advanced disease.soft tissue sarcoma (sts)votrient is indicated for the treatment of adult patients with selective subtypes of advanced soft tissue sarcoma (sts) who have received prior chemotherapy for metastatic disease or who have progressed within 12 months after (neo) adjuvant therapy.

Israel - ebraică - Ministry of Health

novartis israel ltd - pazopanib as hydrochloride - טבליות מצופות פילם - pazopanib as hydrochloride 400 mg - pazopanib - pazopanib - renal cell carcinoma (rcc)votrient is indicated in adults for the first line treatment of advanced renal cell carcinoma (rcc) and for patients who have received prior cytokine therapy for advanced disease.soft tissue sarcoma (sts)votrient is indicated for the treatment of adult patients with selective subtypes of advanced soft tissue sarcoma (sts) who have received prior chemotherapy for metastatic disease or who have progressed within 12 months after (neo) adjuvant therapy.

Israel - ebraică - Ministry of Health

glaxo smith kline (israel) ltd - pazopanib as hydrochloride 200 mg - film coated tablets - pazopanib - renal cell carcinoma (rcc)votrient is indicated in adults for the first line treatment of advanced renal cell carcinoma (rcc) and for patients who have received prior cytokine therapy for advanced disease.soft tissue sarcoma (sts)votrient is indicated for the treatment of adult patients with selective subtypes of advanced soft tissue sarcoma (sts) who have received prior chemotherapy for metastatic disease or who have progressed within 12 months after (neo) adjuvant therapy.

Israel - ebraică - Ministry of Health

glaxo smith kline (israel) ltd - pazopanib as hydrochloride 400 mg - film coated tablets - pazopanib - renal cell carcinoma (rcc)votrient is indicated in adults for the first line treatment of advanced renal cell carcinoma (rcc) and for patients who have received prior cytokine therapy for advanced disease.soft tissue sarcoma (sts)votrient is indicated for the treatment of adult patients with selective subtypes of advanced soft tissue sarcoma (sts) who have received prior chemotherapy for metastatic disease or who have progressed within 12 months after (neo) adjuvant therapy.

Israel - ebraică - Ministry of Health

teva israel ltd - axitinib - טבליות מצופות פילם - axitinib 1 mg - axitinib

Israel - ebraică - Ministry of Health

teva israel ltd - axitinib - טבליות מצופות פילם - axitinib 3 mg - axitinib

Israel - ebraică - Ministry of Health

teva israel ltd - axitinib - טבליות מצופות פילם - axitinib 5 mg - axitinib

Israel - ebraică - Ministry of Health

teva israel ltd - sunitinib as base - קפסולות - sunitinib as base 12.5 mg - sunitinib

Israel - ebraică - Ministry of Health

teva israel ltd - sunitinib as base - קפסולות - sunitinib as base 25 mg - sunitinib

Israel - ebraică - Ministry of Health

teva israel ltd - sunitinib as base - קפסולות - sunitinib as base 37.5 mg - sunitinib